Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease

NACompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

June 30, 2002

Primary Completion Date

August 31, 2014

Study Completion Date

January 31, 2017

Conditions
LymphomaHodgkin's Disease
Interventions
DRUG

Melphalan

"Given on Day -1~Melphalan is administered according to the current SOP."

DRUG

Ara-C

200 mg/m2 IB BID given on Days -5, -4, -3, -2

DRUG

VP-16

200 mg/m2 IV BID given on Days -5, -4, -3, -2

DRUG

BCNU

BCNU 300 mg/m2 IV given on Day -6

DRUG

Rituxan

375 mg/m2 IB given on Days -6, +14, +21, +28

DRUG

Stem Cells

Stem cells given on Day 0

Trial Locations (2)

77030

Texas Children's Hospital, Houston

The Methodist Hospital, Houston

All Listed Sponsors
collaborator

The Methodist Hospital Research Institute

OTHER

collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

lead

Baylor College of Medicine

OTHER

NCT01702961 - Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease | Biotech Hunter | Biotech Hunter